Xiaochun Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaochun Zhang has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Elie Saade
Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
4 shared publicationsAnne Windau
Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA
3 shared publications- Christine Schmotzer
Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
3 shared publications - Jaime H. Noguez
Department of Pathology, Case Western Reserve University School of Medicine , Cleveland, OH
3 shared publications Jamie Meyers
Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA
3 shared publicationsChristine Schmotzer
Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Case Western Reserve University, School of Medicine, Cleveland, OH, USA
2 shared publications
Latest Publications
- 28 July 2025
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 10 (6) , 1638-1657
The Evolving Role of Anti-Müllerian Hormone Measurements in Clinical Practice
Background: Anti-Müllerian hormone (AMH), a glycoprotein belonging to the transforming growth factor-beta superfamily, plays a pivotal role in reproductive physiology. Initially recognized for its function in male sexual differentiation, AMH has since emerged as a key biomarker with broad clinical applications in both endocrinology and oncology. As research continues to elucidate the physiological roles of AMH, its clinical utility is expanding, necessitating careful assay selection, integration with complementary diagnostic markers, and context-specific interpretation. Content: A thorough understanding of AMH physiology, assay variability, and clinical interpretation is essential for its effective integration into routine clinical practice. This review provides a concise overview of AMH physiology, explores its diverse clinical applications, examines the evolution and limitations of AMH assays, and presents a comparative analysis of commercially available AMH assays commonly used in clinical laboratories. Summary: This review highlights the increasing clinical relevance of AMH testing in laboratory medicine, focusing on its expanding applications and the practical analytical considerations essential for accurate interpretation and optimal utilization.
- 28 July 2025
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 10 (6) , 1638-1657
The Evolving Role of Anti-Müllerian Hormone Measurements in Clinical Practice
Background: Anti-Müllerian hormone (AMH), a glycoprotein belonging to the transforming growth factor-beta superfamily, plays a pivotal role in reproductive physiology. Initially recognized for its function in male sexual differentiation, AMH has since emerged as a key biomarker with broad clinical applications in both endocrinology and oncology. As research continues to elucidate the physiological roles of AMH, its clinical utility is expanding, necessitating careful assay selection, integration with complementary diagnostic markers, and context-specific interpretation. Content: A thorough understanding of AMH physiology, assay variability, and clinical interpretation is essential for its effective integration into routine clinical practice. This review provides a concise overview of AMH physiology, explores its diverse clinical applications, examines the evolution and limitations of AMH assays, and presents a comparative analysis of commercially available AMH assays commonly used in clinical laboratories. Summary: This review highlights the increasing clinical relevance of AMH testing in laboratory medicine, focusing on its expanding applications and the practical analytical considerations essential for accurate interpretation and optimal utilization.
- Open Access
- 3 October 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (10) , e0060524
Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters
This study aims to investigate humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and assess the impact of booster vaccines. We recruited individuals scheduled to receive either the first (original formula) or the second (bivalent) booster following the initial two-dose SARS-CoV-2 vaccination. We tested for IgG antibodies targeting the spike protein receptor-binding domain (RBD), S1, S2, and nucleocapsid protein, as well as for neutralizing antibodies against Omicron BA.2, before and 14–28 days after receiving the boosters. One year after receiving the initial series of vaccinations, all participants maintained anti-RBD/S1 antibodies. However, levels were lower in individuals who were vaccinated only compared to those who had both vaccination and prior infection (hybrid immunity). Participants with hybrid immunity also showed higher retention of neutralizing antibodies (93% compared to 24% in vaccine-only individuals). Even before receiving any booster shots, participants with hybrid immunity had antibody levels similar to those of vaccine-only individuals after their first booster. After receiving booster shots, antibody levels at 14–28 days were similar regardless of the number of boosters or the type of immunity. About 1 year after the first booster, all participants maintained neutralizing antibodies, and vaccine-only individuals retained about 10 times higher levels of binding antibodies than those without a booster. Humoral immunity varies widely among individuals, and vaccination planning should consider both vaccination and infection history. Boosters are beneficial for increasing antibody levels to ensure sufficient protection against infection and helping bridge the immunity gap between vaccine-only and hybrid immunity. IMPORTANCE: As we move into the era of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine boosters and shifting from pandemic to endemic, the landscape has changed for both the circulating SARS-CoV-2 variants and population immunity. Even though recent waves of infection have been clinically milder than earlier variants due to the high levels of population immunity and the properties of the Omicron subvariants, vaccination remains crucial for managing COVID-19 in the post-pandemic era. Our study unveils significant variations in the retention of anti-SARS-CoV-2 binding antibody profiles and neutralizing antibody levels 1 year after the primary and the first booster mRNA vaccination. It adds new information regarding how boosters change antibody levels and durability in individuals with hybrid (vaccination plus infection) or vaccine-only (never-infected) immunity. The findings can shed light on future vaccination planning.
- 3 October 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (10) , e0060524
Open AccessDiversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters
This study aims to investigate humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and assess the impact of booster vaccines. We recruited individuals scheduled to receive either the first (original formula) or the second (bivalent) booster following the initial two-dose SARS-CoV-2 vaccination. We tested for IgG antibodies targeting the spike protein receptor-binding domain (RBD), S1, S2, and nucleocapsid protein, as well as for neutralizing antibodies against Omicron BA.2, before and 14–28 days after receiving the boosters. One year after receiving the initial series of vaccinations, all participants maintained anti-RBD/S1 antibodies. However, levels were lower in individuals who were vaccinated only compared to those who had both vaccination and prior infection (hybrid immunity). Participants with hybrid immunity also showed higher retention of neutralizing antibodies (93% compared to 24% in vaccine-only individuals). Even before receiving any booster shots, participants with hybrid immunity had antibody levels similar to those of vaccine-only individuals after their first booster. After receiving booster shots, antibody levels at 14–28 days were similar regardless of the number of boosters or the type of immunity. About 1 year after the first booster, all participants maintained neutralizing antibodies, and vaccine-only individuals retained about 10 times higher levels of binding antibodies than those without a booster. Humoral immunity varies widely among individuals, and vaccination planning should consider both vaccination and infection history. Boosters are beneficial for increasing antibody levels to ensure sufficient protection against infection and helping bridge the immunity gap between vaccine-only and hybrid immunity. IMPORTANCE: As we move into the era of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine boosters and shifting from pandemic to endemic, the landscape has changed for both the circulating SARS-CoV-2 variants and population immunity. Even though recent waves of infection have been clinically milder than earlier variants due to the high levels of population immunity and the properties of the Omicron subvariants, vaccination remains crucial for managing COVID-19 in the post-pandemic era. Our study unveils significant variations in the retention of anti-SARS-CoV-2 binding antibody profiles and neutralizing antibody levels 1 year after the primary and the first booster mRNA vaccination. It adds new information regarding how boosters change antibody levels and durability in individuals with hybrid (vaccination plus infection) or vaccine-only (never-infected) immunity. The findings can shed light on future vaccination planning.
- 12 December 2023
- Published by Springer Nature in Immunologic Research
- Vol. 72 (3) , 361-363
Discouraging Non-ELISA antiphospholipid antibody assays in antiphospholipid syndrome classification may hinder clinical research
- 12 December 2023
- Published by Springer Nature in Immunologic Research
- Vol. 72 (3) , 361-363
Discouraging Non-ELISA antiphospholipid antibody assays in antiphospholipid syndrome classification may hinder clinical research
- 1 December 2023
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 69 (12) , 1342-1346
Positive Syphilis Serologies after Intravenous Immunoglobulin (IVIG) Treatment: A Diagnostic Confusion That Needs Emphasis
- 1 December 2023
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 69 (12) , 1342-1346
Positive Syphilis Serologies after Intravenous Immunoglobulin (IVIG) Treatment: A Diagnostic Confusion That Needs Emphasis
- 16 September 2022
- Published by SAGE Publications in Public Health Reports®
- Vol. 138 (1) , 140-148
SARS-CoV-2 Seroprevalence Among First Responders in Northeastern Ohio, 2020
Objectives: First responders, including firefighters, emergency medical technicians (EMTs), paramedics, and law enforcement officers, are working on the front lines to fight the COVID-19 pandemic and facing an increased risk of infection. This study assessed the seroprevalence of SARS-CoV-2 infection among first responders in northeastern Ohio. Methods: A survey and immunoglobulin G antibody test against SARS-CoV-2 nucleocapsid protein were offered to University Hospitals Health System–affiliated first-responder departments during May to September 2020. The survey contained questions about demographic characteristics and history of SARS-CoV-2 infection. A total of 3080 first responders with diverse job assignments from more than 400 fire and police departments participated in the study. Results: Of 3080 participants, 73 (2.4%) were seropositive and 26 (0.8%) had previously positive real-time polymerase chain reaction results. Asymptomatic infection accounted for 46.6% (34 of 73) of seropositivity. By occupation, rates of seropositivity were highest among administration/support staff (3.8%), followed by paramedics (3.0%), EMTs (2.6%), firefighters (2.2%), and law enforcement officers (0.8%). Work-associated exposure rates to COVID-19 patients were: paramedics (48.2%), firefighters (37.1%), EMTs (32.3%), law enforcement officers (7.7%), and administration/support staff (4.4%). Self-reported community exposure was positively correlated with self-reported work-associated exposure rate (correlation coefficient = 0.99). Neither self-reported community nor work-associated exposure was correlated with SARS-CoV-2 seroprevalence. We found no significant difference in seroprevalence among sex/gender or age groups; however, Black participants had a higher positivity rate than participants of other racial groups despite reporting lower exposure. Conclusions: Despite the high work-associated exposure rate to SARS-CoV-2 infection, first responders with various roles demonstrated seroprevalence no higher than their administrative/supportive colleagues, which suggests infection control measures are effective in preventing work-related infection.
- 16 September 2022
- Published by SAGE Publications in Public Health Reports®
- Vol. 138 (1) , 140-148
SARS-CoV-2 Seroprevalence Among First Responders in Northeastern Ohio, 2020
Objectives: First responders, including firefighters, emergency medical technicians (EMTs), paramedics, and law enforcement officers, are working on the front lines to fight the COVID-19 pandemic and facing an increased risk of infection. This study assessed the seroprevalence of SARS-CoV-2 infection among first responders in northeastern Ohio. Methods: A survey and immunoglobulin G antibody test against SARS-CoV-2 nucleocapsid protein were offered to University Hospitals Health System–affiliated first-responder departments during May to September 2020. The survey contained questions about demographic characteristics and history of SARS-CoV-2 infection. A total of 3080 first responders with diverse job assignments from more than 400 fire and police departments participated in the study. Results: Of 3080 participants, 73 (2.4%) were seropositive and 26 (0.8%) had previously positive real-time polymerase chain reaction results. Asymptomatic infection accounted for 46.6% (34 of 73) of seropositivity. By occupation, rates of seropositivity were highest among administration/support staff (3.8%), followed by paramedics (3.0%), EMTs (2.6%), firefighters (2.2%), and law enforcement officers (0.8%). Work-associated exposure rates to COVID-19 patients were: paramedics (48.2%), firefighters (37.1%), EMTs (32.3%), law enforcement officers (7.7%), and administration/support staff (4.4%). Self-reported community exposure was positively correlated with self-reported work-associated exposure rate (correlation coefficient = 0.99). Neither self-reported community nor work-associated exposure was correlated with SARS-CoV-2 seroprevalence. We found no significant difference in seroprevalence among sex/gender or age groups; however, Black participants had a higher positivity rate than participants of other racial groups despite reporting lower exposure. Conclusions: Despite the high work-associated exposure rate to SARS-CoV-2 infection, first responders with various roles demonstrated seroprevalence no higher than their administrative/supportive colleagues, which suggests infection control measures are effective in preventing work-related infection.
- 28 August 2022
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 104 (4) , 115803
SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays
- 28 August 2022
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 104 (4) , 115803
SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays
- Open Access
- 23 March 2022
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 2 (1) , e47
Seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) among healthcare providers prior to the vaccine era in an integrated midwestern healthcare system
We performed severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antinucleocapsid IgG testing on 5,557 healthcare providers and found a seroprevalence of 3.9%. African Americans were more likely to test positive than Whites, and HCWs with household exposure and those working on COVID-19 cohorting units were more likely to test positive than their peers.
- 23 March 2022
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 2 (1) , e47
Open AccessSeroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) among healthcare providers prior to the vaccine era in an integrated midwestern healthcare system
We performed severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antinucleocapsid IgG testing on 5,557 healthcare providers and found a seroprevalence of 3.9%. African Americans were more likely to test positive than Whites, and HCWs with household exposure and those working on COVID-19 cohorting units were more likely to test positive than their peers.
- Open Access
SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays
Antibody profiling of vaccinated versus naturally infected individuals is important in evaluating immunity and aiding diagnosis and booster strategies. This study measured antibodies against different antigen targets in healthcare workers (HCW) who have been fully vaccinated with mRNA vaccines, recovered from natural infection, or patients during active infection. All vaccinated individuals were positive for anti-RBD, anti-S1, and anti-S2 antibodies. The median index and interquartile range (IQR) by the Atellica IgG assay were 179 and 140-291 respectively. Among the different antigen targets within the Bioplex assay, the levels of anti-RBD were highest (median >3200 U/mL; IQR >3200 to >3200 U/mL), followed by anti-S1 (median 2132 U/mL; IQR 1649->3200 U/mL) and anti-S2 (median=42 U/mL; IQR=24-76 U/mL). The non-vaccinated recovered cohort showed 90% seropositivity (median index >10; IQR 3.6->10) by Atellica total antibody, 73% by Atellica IgG (median index 3.3; IQR 0.9-9.4), 84% by Bioplex anti-RBD (median 62; IQR 12-269 U/mL), 77% by Bioplex anti-S1 (median 45; IQR 10-83 U/mL), 37% by Bioplex anti-S2 (median 7; IQR 1-12 U/mL), and 79% by Bioplex anti-nucleocapsid (median 69; IQR 20-185U/mL) respectively. The active infection cohort exhibited a similar pattern as the recovered cohort. About 88% and 78% of the recovered and active infection cohort produced both anti-spike and anti-N antibodies with Anti-S1/anti-N ratios ranging from 0.07-16.26. In summary, fully vaccinated individuals demonstrated an average of 50-fold higher antibody levels than naturally infected unvaccinated individuals with immune reactivity strongly towards RBD/S1 and a weak response to S2. The results support vaccination regardless of previous COVID-infection status.
Open AccessSARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays
Antibody profiling of vaccinated versus naturally infected individuals is important in evaluating immunity and aiding diagnosis and booster strategies. This study measured antibodies against different antigen targets in healthcare workers (HCW) who have been fully vaccinated with mRNA vaccines, recovered from natural infection, or patients during active infection. All vaccinated individuals were positive for anti-RBD, anti-S1, and anti-S2 antibodies. The median index and interquartile range (IQR) by the Atellica IgG assay were 179 and 140-291 respectively. Among the different antigen targets within the Bioplex assay, the levels of anti-RBD were highest (median >3200 U/mL; IQR >3200 to >3200 U/mL), followed by anti-S1 (median 2132 U/mL; IQR 1649->3200 U/mL) and anti-S2 (median=42 U/mL; IQR=24-76 U/mL). The non-vaccinated recovered cohort showed 90% seropositivity (median index >10; IQR 3.6->10) by Atellica total antibody, 73% by Atellica IgG (median index 3.3; IQR 0.9-9.4), 84% by Bioplex anti-RBD (median 62; IQR 12-269 U/mL), 77% by Bioplex anti-S1 (median 45; IQR 10-83 U/mL), 37% by Bioplex anti-S2 (median 7; IQR 1-12 U/mL), and 79% by Bioplex anti-nucleocapsid (median 69; IQR 20-185U/mL) respectively. The active infection cohort exhibited a similar pattern as the recovered cohort. About 88% and 78% of the recovered and active infection cohort produced both anti-spike and anti-N antibodies with Anti-S1/anti-N ratios ranging from 0.07-16.26. In summary, fully vaccinated individuals demonstrated an average of 50-fold higher antibody levels than naturally infected unvaccinated individuals with immune reactivity strongly towards RBD/S1 and a weak response to S2. The results support vaccination regardless of previous COVID-infection status.
- Open Access
SARS-CoV-2 Seroprevalence among First Responders in Northeastern Ohio
Objectives First responders including firefighters, emergency medical technicians (EMT), paramedics, and police officers are working on the front lines to fight the COVID-19 pandemic and facing a higher risk of infection. This study assessed the seroprevalence among first responders in northeastern Ohio during May-September 2020. Methods A survey and IgG antibody test against SARS-CoV-2 were offered to University Hospitals Health System affiliated first responder departments. Results A total of 3080 first responders with diverse job assignments from more than 400 fire and police departments participated in the study. Among them, 73 (2.4%) were seropositive while only 0.8% had previously positive RT-PCR results. Asymptomatic infection accounts for 46.6% of seropositivity. By occupation, seropositive rates were highest among administration/support staff (3.8%), followed by paramedics (3.0%), EMTs (2.6%), firefighters (2.2%), and police officers (0.8%). Seroprevalence was not associated with self-reported exposure as work exposure rates were: paramedics 48.2%, firefighters 37.1%, EMTs 32.3%, police officers 7.7%, and administration/support staff 4.4%. Self-reported community exposure was strongly correlated with self-reported work exposure rate rather than seroprevalence suggesting a potential impact of risk awareness. Additionally, no significant difference was found among gender or age groups; however, black Americans have a higher positivity rate than other races although they reported lower exposure. Conclusions Despite the high work-associated exposure rate to SARS-CoV-2 infection, first responders with different roles demonstrated seroprevalence no higher than their administrative/supportive colleagues, which suggests infection control measures are effective in preventing work-related infection.
Open AccessSARS-CoV-2 Seroprevalence among First Responders in Northeastern Ohio
Objectives First responders including firefighters, emergency medical technicians (EMT), paramedics, and police officers are working on the front lines to fight the COVID-19 pandemic and facing a higher risk of infection. This study assessed the seroprevalence among first responders in northeastern Ohio during May-September 2020. Methods A survey and IgG antibody test against SARS-CoV-2 were offered to University Hospitals Health System affiliated first responder departments. Results A total of 3080 first responders with diverse job assignments from more than 400 fire and police departments participated in the study. Among them, 73 (2.4%) were seropositive while only 0.8% had previously positive RT-PCR results. Asymptomatic infection accounts for 46.6% of seropositivity. By occupation, seropositive rates were highest among administration/support staff (3.8%), followed by paramedics (3.0%), EMTs (2.6%), firefighters (2.2%), and police officers (0.8%). Seroprevalence was not associated with self-reported exposure as work exposure rates were: paramedics 48.2%, firefighters 37.1%, EMTs 32.3%, police officers 7.7%, and administration/support staff 4.4%. Self-reported community exposure was strongly correlated with self-reported work exposure rate rather than seroprevalence suggesting a potential impact of risk awareness. Additionally, no significant difference was found among gender or age groups; however, black Americans have a higher positivity rate than other races although they reported lower exposure. Conclusions Despite the high work-associated exposure rate to SARS-CoV-2 infection, first responders with different roles demonstrated seroprevalence no higher than their administrative/supportive colleagues, which suggests infection control measures are effective in preventing work-related infection.
- Open Access
- 1 August 2020
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 21, e00160
A one-step NIST traceable HPLC method for quantitation of vitamin B6 and 4-pyridoxic acid in human plasma
- 1 August 2020
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 21, e00160
Open AccessA one-step NIST traceable HPLC method for quantitation of vitamin B6 and 4-pyridoxic acid in human plasma